LivaNova PLC (LIVN)
NASDAQ:LIVN
Want to see LIVN full AI Analyst Report?
LIVN Stock Chart & Stats
$67.12
$0.70(1.49%)
At close: 4:00 PM EST
$67.12
$0.70(1.49%)
Day’s Range― - ―
52-Week Range$41.02 - $74.41
Previous CloseN/A
Volume66.13K
Average Volume (3M)836.90K
Market Cap
$4.06B
Enterprise Value$3.85B
Total Cash (Recent Filing)$539.70M
Total Debt (Recent Filing)$334.50M
Price to Earnings (P/E)39.0
Beta0.98
Next Earnings
Jul 29, 2026EPS Estimate
1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.97
Shares Outstanding54,933,537
10 Day Avg. Volume739,896
30 Day Avg. Volume836,900
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.79
Price to Sales (P/S)2.42
P/FCF Ratio19.36
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue2.69
Enterprise Value/Gross Profit3.98
Enterprise Value/Ebitda16.53
Forecast
1Y Price Target
$80.00Price Target Upside19.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)4.25
Revenue Forecast (FY)$1.51B
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceA large randomized controlled trial showed efficacy across diverse and challenging patient groups, strengthening confidence in the technology's clinical value and commercial appeal.
Profitability OutlookManagement's expectation that the OSA business can reach cash-flow neutrality with margins above company averages points to attractive long-term profitability potential for the neuromodulation franchise.
Regulatory ApprovalFDA premarket approval for the aura6000 enables market entry into obstructive sleep apnea treatment, opening a new revenue stream from patients not well served by existing devices.
Bears Say
Cardiopulmonary PerformanceSlowing growth in the cardiopulmonary division could weigh on overall revenue momentum and constrain upside to company results.
Legal OverhangOngoing Italian SNIA litigation remains an overhang that could damp investor confidence and create uncertainty until a final resolution is reached.
Supply ConstraintsComponent-related supply limits cited in guidance could cap product shipments and revenue if supply conditions do not improve as expected.
LivaNova News
LIVN FAQ
What was LivaNova PLC’s price range in the past 12 months?
LivaNova PLC lowest stock price was $41.02 and its highest was $74.41 in the past 12 months.
What is LivaNova PLC’s market cap?
LivaNova PLC’s market cap is $4.06B.
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is Jul 29, 2026 which is in 66 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on May 06, 2026. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.897 by $0.083.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is 1.09.
How many shares outstanding does LivaNova PLC have?
LivaNova PLC has 54,933,537 shares outstanding.
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of $0.98 in its last earnings report, beating expectations of $0.897. Following the earnings report the stock price went up 15.055%.
Which hedge fund is a major shareholder of LivaNova PLC?
Currently, no hedge funds are holding shares in LIVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LivaNova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$80.00 (19.19% Upside)
$80.00 (19.19% Upside)
Blogger Sentiment
Bullish
LIVN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 874.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.9%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.98%
12-Months-Change
Fundamentals
Return on Equity
9.13%
Trailing 12-Months
Asset Growth
-1.66%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
LIVN Company Deck
LIVN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivered multiple material positive developments: double-digit Q1 revenue growth, upward revisions to full-year revenue and EPS guidance, regulatory approval and robust clinical evidence in OSA, meaningful reimbursement improvement for VNS in the U.S., strong cardiopulmonary momentum (Essenz upgrade and manufacturing expansion) and clinical differentiation (PolySync). Headwinds exist—near-term cash and free cash flow pressures driven by higher capex, working capital and a one-time bonus payout; modest gross margin compression; ongoing third-party supply constraints and reimbursement/coding uncertainty for HGNS and DTTD—which the company is actively addressing. On balance, the positives (revenue/earnings upgrades, regulatory/clinical milestones, market share gains and manufacturing expansion plans) outweigh the lowlights, indicating strong operational momentum while the company invests for growth and manages known near-term pressures.View all LIVN earnings summariesLIVN Stock 12 Month Forecast
Average Price Target
$80.00
▲(19.19% Upside)
Technical Analysis
Artivion
―
Integer Holdings
―
Ufp Technologies
―
Inspire Medical Systems
―
TransMedics Group
―
Ownership Overview
0.37% Insiders
30.30% Mutual Funds
31.49% Other Institutional Investors
14.59% Public Companies and
Individual Investors